BRIEF published on 09/25/2025 at 20:21, 7 months 21 days ago ABIONYX Pharma : Résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie Plan France 2030 ABIONYX Pharma
PRESS RELEASE published on 09/25/2025 at 20:16, 7 months 21 days ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
PRESS RELEASE published on 09/25/2025 at 20:16, 7 months 21 days ago Informations privilégiées / Communiqué sur comptes, résultats ABIONYX Pharma annonce ses résultats financiers du 1er semestre 2025. Chiffre d'affaires de 2,1 M€, pertes réduites. Trésorerie à 3,4 M€. Lauréat du plan France 2030 Chiffre D'affaires Résultats Financiers Trésorerie ABIONYX Pharma 1er Semestre 2025
PRESS RELEASE published on 09/25/2025 at 18:58, 7 months 21 days ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
BRIEF published on 08/28/2025 at 18:56, 8 months 19 days ago Bilan semestriel 2025 d'ABIONYX Pharma Chiffre D'affaires Trésorerie ABIONYX Pharma Soutien Financier Semestre 2025
BRIEF published on 08/28/2025 at 18:56, 8 months 19 days ago ABIONYX Pharma 2025 half-year review Treasury Financial Support Turnover ABIONYX Pharma Semester 2025
PRESS RELEASE published on 08/28/2025 at 18:51, 8 months 19 days ago Inside Information / Other news releases ABIONYX Pharma provided an update on its activity and cash position for Q2 2025. Company's revenue, cash position, and government funding details revealed Revenue Cash Position Update Government Funding ABIONYX Pharma
PRESS RELEASE published on 08/28/2025 at 18:51, 8 months 19 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma fait le point sur son activité et sa trésorerie du 1er semestre 2025, notamment un chiffre d'affaires de 2,1 M€ provenant de sa filiale IRIS Pharma. La trésorerie s'établit à 3,4 M€ Chiffre D'affaires Biotechnologie Trésorerie ABIONYX Pharma Thérapies Innovantes
BRIEF published on 08/27/2025 at 19:31, 8 months 20 days ago ABIONYX Pharma en pourparlers pour un partenariat stratégique dans le sepsis Partenariat Stratégique ABIONYX Pharma Sepsis CER-001 Thérapies Innovantes
BRIEF published on 08/27/2025 at 19:31, 8 months 20 days ago ABIONYX Pharma in talks for a strategic partnership in sepsis Strategic Partnership Innovative Therapies ABIONYX Pharma Sepsis CER-001
Published on 05/16/2026 at 01:15, 1 day 10 hours ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 1 day 11 hours ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 1 day 12 hours ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/15/2026 at 23:00, 1 day 12 hours ago Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency
Published on 05/16/2026 at 16:08, 19 hours 47 minutes ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 1 day 15 hours ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 1 day 17 hours ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 15:08, 1 day 20 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 1 day 20 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 2 days 1 hour ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 3 days 2 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 3 days 17 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
